

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

Luminex: 100 Flow Cytometry Analyzer System

RRID:SCR_018025

Type: Tool

Proper Citation

Luminex: 100 Flow Cytometry Analyzer System (RRID:SCR_018025)

Resource Information

URL: https://pedsresearch.org/uploads/pages/img/LuminexManual_LX100.pdf

Proper Citation: Luminex: 100 Flow Cytometry Analyzer System (RRID:SCR_018025)

Description: Flow cytometry analyzer system for individual labs that performs up to 100 different tests in single reaction volume and can use either magnetic beads or plain polystyrene beads.

Synonyms: Luminex 100 System

Resource Type: instrument resource

Keywords: ABRF, suspension array analyzer, flow cytometry, magnetic bead, polystyrene bead, analysis, Luminex Corporation, instrument, equipment

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018025.pdf

Resource Name: Luminex: 100 Flow Cytometry Analyzer System

Resource ID: SCR_018025

Old URLs: <https://www.luminexcorp.com/research-luminex-100200/>

Record Creation Time: 20220129T080338+0000

Record Last Update: 20260905T132829+0000

Ratings and Alerts

No rating or validation information has been found for Luminex: 100 Flow Cytometry Analyzer System.

No alerts have been found for Luminex: 100 Flow Cytometry Analyzer System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Sirc N, et al. (2026) Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models. *Cancer research communications*, 6(2), 402.

Lee E, et al. (2026) Angiopoietin-2 aggravates Alzheimer's disease by promoting blood-brain barrier dysfunction and neuroinflammation. *Cell reports*, 116621.

Ye J, et al. (2026) Baseline Tumor Features and Systemic Immune Dynamics Underlying Efficacy in MSS Metastatic Colorectal Cancer Treated with Regorafenib, Ipilimumab, and Nivolumab. *Cancer immunology research*, 14(4), 585.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. *Cancer research*, 86(11), 2688.

Teras LR, et al. (2026) Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts. *Blood cancer journal*, 16(1).

Digomann D, et al. (2025) Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. *iScience*, 28(11), 113871.

Bartkeviciene A, et al. (2025) Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. *Frontiers in immunology*, 16, 1655258.

Mousavi T, et al. (2025) Polyomaviruses and the risk of breast cancer: a systematic review and meta-analysis. *Infectious agents and cancer*, 20(1), 14.

Rebhun RB, et al. (2025) Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. *Frontiers in immunology*, 16, 1672790.

von Itzstein MS, et al. (2025) Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(4), 639.

MacDonald WJ, et al. (2025) Inhibition of ITGB6 stimulates potent anti-tumor responses in immunocompetent mouse models of head and neck squamous cell carcinoma and pancreatic adenocarcinoma. *American journal of cancer research*, 15(12), 5317.

Huntington KE, et al. (2023) GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. *International journal of molecular sciences*, 24(13).

Huntington KE, et al. (2023) GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. *bioRxiv : the preprint server for biology*.

Cognasse F, et al. (2023) Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. *EBioMedicine*, 87, 104414.

Krishna BA, et al. (2022) Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. *EBioMedicine*, 81, 104129.

Ertveldt T, et al. (2022) Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. *Molecular cancer therapeutics*, 21(7), 1136.

Ji S, et al. (2022) Jia Wei Xiao Yao San ameliorates chronic stress-induced depression-like behaviors in mice by regulating the gut microbiome and brain metabolome in relation to purine metabolism. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 98, 153940.

Rappe JCF, et al. (2021) A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza. *The Journal of experimental medicine*, 218(11).

Piccinni MP, et al. (2021) Description of the Follicular Fluid Cytokine and Hormone Profiles in Human Physiological Natural Cycles. *The Journal of clinical endocrinology and metabolism*, 106(2), e721.

Martínez-Blanco Á, et al. (2021) CD38 Deficiency Ameliorates Chronic Graft-Versus-Host Disease Murine Lupus via a B-Cell-Dependent Mechanism. *Frontiers in immunology*, 12, 713697.